Siegfried Aktiengesellschaft

Siegfried Aktiengesselschaft

Ulrich Jahn

Kurt Thiele

Rudolf Adrian

Quazi Ahmed

Ludwig Zirngibl

Felix Geissmann

Johanna Fischer

Istvan Molnar

Theodor W Wagner-Jauregg

Quazi Armed

James S Cox

Franz Schatz

Christian Stammbach

New derivatives of theophylline having the formula ##STR1## wherein R is hydrogen or a hydroxy group, and n is an integer of 0.ltoreq.n.ltoreq.3 and/or the pharmaceutically acceptable, acid addition salts thereof, exhibit in addition to other properties, histamine-serotinine- bradykynine- antagonistic, anti-anaphylactic and .beta.-adrenergic stimulating effects.

P-fluorobenzoyl-piperidino alkyl theophylline derivatives

New derivatives of theophylline having the formula ##STR1## in which R denotes hydrogen or OH, n the numbers 0 or 1, X either &gt;CH-- or &gt;N--, Y either --O-- or --CO-- and R a five membered or six membered aryl ring or hetero-aryl ring, that is substituted in given cases with halogen, short chain alkyl groups, alkoxy groups or halogen-alkyl, and exhibit in addition to other properties, histamine-, serotinine- bradykynine- antagonistic, anti-anaphylactic and -adrenergic stimulating effects.

Theophylline derivatives

4-(2-Imidazolin-2-yl-amino)-2-methyl-indazole is a highly selective and effective .alpha..sub.2 -antagonist, .alpha..sub.1 -partial agonist and .alpha..sub.1s -agonist and displays anti-hypertensive activity and antagonistic activity on adrenaline and noradrenaline. It is useful as an .alpha.-adrenoceptor influencing and as an anti-hypertensively active drug.

Antihypertensive 4-(2-imidazolin-2-yl-amino)-2-methyl-indazole

Novel compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, halogen, or alkyl or alkoxy containing from 1 to 4 carbon atoms,

Phenoxy alkanoic acid derivatives having the ability to lower the level

1H- and 2H- indazole derivatives

Therapeutic xanthine oxidase inhibitor composition containing as an active ingredient 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine dihydrate of the formula ##STR1## Uratic diathesis in warm-blooded animals is therapeutically treated by administering the aforementioned xanthine oxidase inhibitor to such animals, e.g., human, either orally or by means of an injection, thereby inhibiting their xanthine oxidase activity.

Xanthine oxidase inhibitor and therapeutic treatment using same

Novel alkylene glycol derivatives of the formula (1) ##STR1## in which R.sup.1 is the hydrogen atom, an alkyl group having 1-4 C-atoms or an aryl group, R.sup.2 is the hydrogen atom or an alkyl group having 1-4 C-atoms, R.sup.3 is the hydrogen atom or a group of the formula ##STR2## in which Z is an alkyl residue, an optionally substituted aryl residue or a heterocyclic residue and R.sup.4 is a residue of the formula ##STR3## in which R.sup.5 is the hydrogen atom or chlorine atom, or the methyl group, exhibit an advantageous activity in regard of lowering the cholesterol and triglyceride level in the blood. Production of the novel derivatives by reduction of the corresponding acids, or by reacting a phenol of the formula ##STR4## and an alcohol of the formula ##STR5## optionally with subsequent esterification, is described.

Lipid lowering alkylene glycols and ester derivatives thereof

Novel compounds of the formula (1) ##STR1## wherein R.sup.1 and R.sup.2 are different lower alkyls and R.sup.3 is a lower alkyl or a methyl pyridine group, and the acid addition salts of formula (1) compounds when R.sup.3 is methyl pyridine. The novel compounds have an asymmetric C-atom and may be in the form of the D,L racemates or the D or L stereoisomers. These compounds are useful in the treatment of hypercholesterolemia and hyperlipidemia because of their high effectiveness in reducing the level of cholesterol and lipids in the blood combined with very low general toxicities and substantially reduced hepatomegalitic effects.

Chlorobenzyl phenoxy alkoxylates

Novel hydrazines are disclosed in which one of the nitrogen atoms forms a ring member of the five membered ring of a [4.3.0] heterobicyclic compound which may be substituted elsewhere in the ring system. Characteristic ring systems described include indole and benztriazole ring systems. The compounds possess anti-depressant properties as well as anti-microbial, in particular fungistatic and bacteriostatic, properties.

N-Amino indole derivatives having pharmacological activity

Novel cholesterol-lowering compounds

Compounds possessing pharmaceutical activity as substances able to lower the level of fatty substances in the blood possess the following general formula: ##STR1## wherein R represents hydrogen, halogen, hydroxy or alkyl or alkoxy containing from 1 to 4 carbon atoms;

Cholesterol-lowering phenoxyalkanoic acid esters

Compounds of the formula ##STR1## WHEREIN R represents hydrogen, halogen, hydroxy or alkyl or alkoxy containing from 1 to 4 carbon atoms;

Pyridyl alkyl esters of substituted phenoxy alkanoic acids having the

Indolyl alkyl amines of the following formula: ##SPC1## And their salts with organic or inorganic acids. In this formula I, A and A.sup.1 denote identical or different alkyl radicals which both together have a total of 3-8 C-atoms. R.sup.1 denotes hydrogen, a lower alkyl radical having up to 4 C-atoms or a possibly substituted benzyl or benzoyl radical. R.sup.2 and R.sup.3 may be the same or different and denote hydrogen, a halogen (more particularly chlorine, bromine or fluorine) or (possibly halogenated) lower alkyl radicals or (possibly etherified) hydroxy radicals. R.sup.4 denotes hydrogen, a lower alkyl radical, an acyl group or a (possibly substituted) benzyl radical or the cyano-ethyl group. The compounds are useful as anoretics (appetite inhibitors) and can be made by various disclosed methods.

Growing community of inventors

Zofingen, Switzerland

Ulrich Jahn